ClinicalTrials.gg
CompletedNCT00861757Updated Jun 28, 2011Results posted

Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia

A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 6 sites in 2 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
4th of 26
612 · median 258
Started
2009
with 4 others
Phase 3
10 of 26
none open now
Registered
9th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 4th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 9th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia (BPH).

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asian males, with benign prostatic hyperplasia (BPH) for at least 6 months prior to initiation and IPSS score greater than or equal to 13 at the beginning of the treatment
  • Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and overactive bladder (OAB) treatments at any time during the study.
  • Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to the beginning of the treatment

Exclusion criteria

Exclusion Criteria:

  • Prostate specific antigen (PSA) score beyond acceptable range defined for study at initiation
  • History of urinary retention or lower urinary tract (bladder) stones within 6 months of initiation
  • History of urinary urethral obstruction due to stricture, valves, sclerosis, or tumor at initiation
  • Clinical evidence of prostate cancer at initiation
  • Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at initiation
  • History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study
  • History of significant central nervous system injuries (including stroke or spinal cord injury within 6 months of initiation)
  • Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (LHRH)agonists/antagonists, or anabolic steroids at initiation
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
612 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    2.5 mg Tadalafil

    Drug: Tadalafil

  • Experimental
    5.0 mg Tadalafil

    Drug: Tadalafil

  • Active comparator
    0.2 mg Tamsulosin

    Drug: Tamsulosin

Interventions

  • by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks

    Also known as: LY450190, Cialis

  • DrugPlacebo

    PO, QD (30 min after meal) for 12 weeks

  • PO, QD (30 min after meal) for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks

    The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.

    Time frame: baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])

    IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

    Time frame: baseline, 12 weeks

  2. Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks

    Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

    Time frame: baseline, 12 weeks

  3. Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks

    The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.

    Time frame: baseline, 12 weeks

  4. Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks

    Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

    Time frame: baseline, 12 weeks

  5. Patient Global Impression of Improvement (PGI-I) at Week 12

    The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).

    Time frame: 12 weeks

  6. Clinician Global Impression of Improvement (CGI-I) at Week 12

    The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).

    Time frame: 12 weeks

  7. Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks

    Nanograms of PSA per milliliter (ng/mL) of blood.

    Time frame: baseline, 12 weeks

  8. Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks

    The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.

    Time frame: baseline, 12 weeks

  9. Change From Baseline in Blood Pressure (Sitting) at 12 Weeks

    Time frame: baseline, 12 weeks

  10. Change From Baseline in Blood Pressure (Standing) at 12 Weeks

    Time frame: baseline, 12 weeks

  11. Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks

    Time frame: baseline, 12 weeks

07

Results

Posted Jun 13, 2011

Participant flow

Participant flow — Overall Study
MilestonePlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Started154151155152
Completed145136137143
Not completed915189
Withdrew: Adverse event1572
Withdrew: Entry criteria not met1211
Withdrew: Lack of efficacy3101
Withdrew: Lost to follow-up1011
Withdrew: Physician decision0001
Withdrew: Protocol violation2241
Withdrew: Withdrawal by subject1552

Outcome measures

PrimaryChange From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks

The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.

Time frame:
baseline, 12 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks
Units on a scalePlacebo2.5 mg Tadalafil5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks-3.0 ± 0.4-4.8 ± 0.4-4.7 ± 0.4-5.5 ± 0.4
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.003 · Mean difference (final values): -1.8 · 95% CI -3.0 to -0.6
  • Placebo vs 5 mg Tadalafil · ANCOVA · p = 0.004 · Mean difference (final values): -1.7 · 95% CI -2.9 to -0.6
  • Placebo vs 0.2 mg Tamsulosin · ANCOVA · p = <0.001 · Mean difference (final values): -2.5 · 95% CI -3.7 to -1.3
SecondaryChange From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])

IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

Time frame:
baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])
units on a scalePlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Voiding (Obstructive) Score (N = 154,151,155,152)-1.9 ± 0.3-3.3 ± 0.3-3.0 ± 0.3-3.8 ± 0.3
Storage (Irritative) Score (N = 154,151,155,152)-1.1 ± 0.2-1.5 ± 0.2-1.7 ± 0.2-1.7 ± 0.2
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = <0.001 (This is the p value for the Voiding (Obstructive) Score.) · Mean difference (final values): -1.4 · 95% CI -2.2 to -0.6
  • Placebo vs 5.0 mg Tadalafil · ANCOVA · p = 0.005 (This is the p value for the Voiding (Obstructive) Score.) · Mean difference (final values): -1.1 · 95% CI -1.9 to -0.3
  • Placebo vs 0.2 mg Tamsulosin · ANCOVA · p = <0.001 (This is the p value for the Voiding (Obstructive) Score.) · Mean difference (final values): -1.9 · 95% CI -2.7 to -1.1
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.072 (This is the p value for the Storage (Irritative) Score.) · Mean difference (final values): -0.5 · 95% CI -1.0 to 0.0
  • Placebo vs 5.0 mg Tadalafil · ANCOVA · p = 0.021 (This is the p value for the Storage (Irritative) Score.) · Mean difference (final values): -0.6 · 95% CI -1.1 to -0.1
  • Placebo vs 0.2 mg Tamsulosin · ANCOVA · p = 0.023 (This is the p value for the Storage (Irritative) Score.) · Mean difference (final values): -0.6 · 95% CI -1.1 to -0.1
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks

Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

Time frame:
baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks
units on a scalePlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks-0.5 ± 0.1-0.8 ± 0.1-0.8 ± 0.1-1.1 ± 0.1
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.031 · Mean difference (final values): -0.3 · 95% CI -0.6 to -0.0
  • Placebo vs 5.0 mg Tadalafil · ANCOVA · p = 0.013 · Mean difference (final values): -0.3 · 95% CI -0.6 to -0.1
  • Placebo vs 0.2 mg Tamsulosin · ANCOVA · p = <0.001 · Mean difference (final values): -0.6 · 95% CI -0.9 to -0.4
SecondaryChange From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks

The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.

Time frame:
baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks
units on a scalePlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks-0.8 ± 0.2-1.1 ± 0.2-1.0 ± 0.2-1.6 ± 0.2
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.201 · Mean difference (final values): -0.4 · 95% CI -1.0 to 0.2
  • Placebo vs 5.0 mg Tadalafil · ANCOVA · p = 0.393 · Mean difference (final values): -0.2 · 95% CI -0.8 to 0.3
  • Placebo vs 0.2 mg Tamsulosin · ANCOVA · p = 0.007 · Mean difference (final values): -0.8 · 95% CI -1.4 to -0.2
SecondaryChange From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks

Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

Time frame:
baseline, 12 weeks
Reported as:
Least squares mean · milliliter per second (mL/sec)
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks
milliliter per second (mL/sec)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks2.1 ± 0.41.6 ± 0.41.3 ± 0.42.1 ± 0.4
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · ANCOVA · p = 0.331 · Mean difference (final values): -0.5 · 95% CI -1.6 to 0.5
  • Placebo vs 5.0 mg Tadalafil · ANCOVA · p = 0.140 · Mean difference (final values): -0.8 · 95% CI -1.8 to 0.3
  • Placebo vs 0.2 mg Tamsulosin · ANCOVA · p = 0.940 · Mean difference (final values): -0.0 · 95% CI -1.1 to 1.0
SecondaryPatient Global Impression of Improvement (PGI-I) at Week 12

The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).

Time frame:
12 weeks
Reported as:
Number · Participants
Patient Global Impression of Improvement (PGI-I) at Week 12
ParticipantsPlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Very Much Worse2110
Much Worse3101
A Little Worse12454
No Change45262325
A Little Better54627458
Much Better32444053
Very Much Better49109
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Cochran-Mantel-Haenszel · p = <0.001 (The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 2.5 mg Tadalafil) and 7 categories of the PGI-I.)
  • Placebo vs 5.0 mg Tadalafil · Cochran-Mantel-Haenszel · p = <0.001 (The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 5.0 mg Tadalafil) and 7 categories of the PGI-I.)
  • Placebo vs 0.2 mg Tamsulosin · Cochran-Mantel-Haenszel · p = <0.001 (The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (placebo vs 0.2 mg Tamsulosin) and 7 categories of the PGI-I.)
SecondaryClinician Global Impression of Improvement (CGI-I) at Week 12

The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).

Time frame:
12 weeks
Reported as:
Number · participants
Clinician Global Impression of Improvement (CGI-I) at Week 12
participantsPlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Very Much Worse0200
Much Worse3311
A Little Worse8433
No Change44212919
A Little Better60676268
Much Better30394847
Very Much Better7111012
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Cochran-Mantel-Haenszel · p = 0.034 (The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 2.5 mg Tadalafil) and 7 categories of the CGI-I.)
  • Placebo vs 5.0 mg Tadalafil · Cochran-Mantel-Haenszel · p = 0.002 (The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 5.0 mg Tadalafil) and 7 categories of the CGI-I.)
  • Placebo vs 0.2 mg Tamsulosin · Cochran-Mantel-Haenszel · p = 0.001 (The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 0.2 mg Tamsulosin) and 7 categories of the CGI-I.)
SecondaryChange From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks

Nanograms of PSA per milliliter (ng/mL) of blood.

Time frame:
baseline, 12 weeks
Reported as:
Mean · microgram/Liter
Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks
microgram/LiterPlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks-0.03 ± 0.550.04 ± 0.540.13 ± 0.59-0.06 ± 0.61
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.412
  • Placebo vs 5.0 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.083
  • Placebo vs 0.2 mg Tamsulosin · Wilcoxon (Mann-Whitney) · p = 0.456
SecondaryChange From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks

The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.

Time frame:
baseline, 12 weeks
Reported as:
Mean · milliliter (mL)
Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks
milliliter (mL)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks-1.20 ± 45.35-0.09 ± 45.21-2.90 ± 48.84-5.67 ± 34.38
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.688
  • Placebo vs 5.0 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.510
  • Placebo vs 0.2 mg Tamsulosin · Wilcoxon (Mann-Whitney) · p = 0.212
SecondaryChange From Baseline in Blood Pressure (Sitting) at 12 Weeks
Time frame:
baseline, 12 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Blood Pressure (Sitting) at 12 Weeks
mm HgPlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Systolic Blood Pressure0.9 ± 10.9-2.3 ± 11.0-0.5 ± 12.40.2 ± 12.2
Diastolic Blood Pressure-0.3 ± 8.6-2.5 ± 7.8-1.4 ± 8.1-0.6 ± 7.9
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.005 (This is the p value for systolic blood pressure.)
  • Placebo vs 5.0 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.274 (This is the p value for systolic blood pressure.)
  • Placebo vs 0.2 mg Tamsulosin · Wilcoxon (Mann-Whitney) · p = 0.538 (This is the p value for systolic blood pressure.)
  • Placebo vs 2.5 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.008 (This is the p value for diastolic blood pressure.)
  • Placebo vs 5.0 mg Tadalafil · Wilcoxon (Mann-Whitney) · p = 0.216 (This is the p value for diastolic blood pressure.)
  • Placebo vs 0.2 mg Tamsulosin · Wilcoxon (Mann-Whitney) · p = 0.524 (This is the p value for diastolic blood pressure.)
SecondaryChange From Baseline in Blood Pressure (Standing) at 12 Weeks
Time frame:
baseline, 12 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Blood Pressure (Standing) at 12 Weeks
mm HgPlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Systolic Blood Pressure0.8 ± 11.8-2.9 ± 12.30.6 ± 11.6-0.9 ± 13.7
Diastolic Blood Pressure0.4 ± 8.1-2.3 ± 8.0-1.7 ± 8.2-1.0 ± 8.8
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Wilcoxon rank-sum test · p = 0.007 (This is the p value for systolic blood pressure.)
  • Placebo vs 5.0 mg Tadalafil · Wilcoxon rank-sum test · p = 0.723 (This is the p value for systolic blood pressure.)
  • Placebo vs 0.2 mg Tamsulosin · Wilcoxon rank-sum test · p = 0.273 (This is the p value for systolic blood pressure.)
  • Placebo vs 2.5 mg Tadalafil · Wilcoxon rank-sum test · p = 0.005 (This is the p value for diastolic blood pressure.)
  • Placebo vs 5.0 mg Tadalafil · Wilcoxon rank-sum test · p = 0.054 (This is the p value for diastolic blood pressure.)
  • Placebo vs 0.2 mg Tamsulosin · Wilcoxon rank-sum test · p = 0.278 (This is the p value for diastolic blood pressure.)
SecondaryChange From Baseline in Sitting Heart Rate (HR) at 12 Weeks
Time frame:
baseline, 12 weeks
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks
beats per minute (bpm)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks-0.3 ± 8.90.7 ± 8.30.6 ± 8.30.6 ± 7.8
Statistical analysis
  • Placebo vs 2.5 mg Tadalafil · Wilcoxon rank-sum test · p = 0.330
  • Placebo vs 5.0 mg Tadalafil · Wilcoxon rank-sum test · p = 0.838
  • Placebo vs 0.2 mg Tamsulosin · Wilcoxon rank-sum test · p = 0.409

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/154 (0.6%)24/154 (15.6%)
2.5 mg Tadalafil—4/151 (2.6%)38/151 (25.2%)
5.0 mg Tadalafil—0/155 (0%)42/155 (27.1%)
0.2 mg Tamsulosin—0/152 (0%)35/152 (23%)
Most frequent serious events
Most frequent serious events
EventPlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
InjuryInjury, poisoning and procedural complications0/1541/1510/1550/152
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1541/1510/1550/152
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1541/1510/1550/152
Hepatic cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1541/1510/1550/152
HypertensionVascular disorders0/1541/1510/1550/152
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1540/1510/1550/152
Most frequent other events
Showing 10 of 103
Most frequent other events
EventPlacebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg Tamsulosin
MyalgiaMusculoskeletal and connective tissue disorders0/1543/1516/1550/152
Back painMusculoskeletal and connective tissue disorders1/1541/1514/1551/152
NasopharyngitisInfections and infestations3/1543/1512/1551/152
DizzinessNervous system disorders0/1543/1510/1552/152
HeadacheNervous system disorders1/1543/1513/1551/152
Hepatic function abnormalHepatobiliary disorders3/1540/1510/1551/152
NauseaGastrointestinal disorders0/1540/1513/1550/152
DiarrhoeaGastrointestinal disorders0/1542/1512/1551/152
ArthralgiaMusculoskeletal and connective tissue disorders0/1542/1510/1551/152
Muscle spasmsMusculoskeletal and connective tissue disorders1/1542/1510/1550/152

Baseline characteristics

Age Continuous
Age Continuous(years)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Mean63.7 ± 8.163.7 ± 7.262.3 ± 8.062.6 ± 7.963.1 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Female00000
Male154151155152612
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Asian154151155152612
Region of Enrollment
Region of Enrollment(participants)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Taiwan2423212290
Japan86848785342
Korea, Republic of44444745180
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meters (kg/m^2))Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Mean24.3 ± 2.923.9 ± 2.824.2 ± 2.824.4 ± 2.924.2 ± 2.8
Current Tobacco Use
Current Tobacco Use(participants)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Yes27303623116
No127121119129496
Current Alcohol Use
Current Alcohol Use(participants)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Yes78818483326
No76707169286
Benign Prostatic Hyperplasia (BPH) Severity
Benign Prostatic Hyperplasia (BPH) Severity(participants)Placebo2.5 mg Tadalafil5.0 mg Tadalafil0.2 mg TamsulosinTotal
Moderate (IPSS<20)102102102102408
Severe (IPSS>=20)52495350204

7 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 663-8006, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 565-0854, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 130-0026, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 813, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 100, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tao-Yuan, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2009
First posted
Mar 13, 2009
Start
Mar 2009
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
Jun 13, 2011
Last update
Jun 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00861757
First posted
Mar 13, 2009
Start date
Mar 2009
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Jun 13, 2011
Last update
Jun 28, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion